` 300765 (CSPC Innovation Pharmaceutical Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

300765
vs
Shanghai Composite

Over the past 12 months, has outperformed Shanghai Composite, delivering a return of 25% compared to the Shanghai Composite's 7% growth.

Stocks Performance
300765 vs Shanghai Composite

Loading

Performance Gap
300765 vs Shanghai Composite

Loading
300765
Shanghai Composite
Difference

Performance By Year
300765 vs Shanghai Composite

Loading
300765
Shanghai Composite
Add Stock

Competitors Performance
CSPC Innovation Pharmaceutical Co Ltd vs Peers

Shanghai Composite
300765
LLY
JNJ
NOVO B
ROG
Add Stock

CSPC Innovation Pharmaceutical Co Ltd
Glance View

Market Cap
111.9B CNY
Industry
Pharmaceuticals

Nestled in the dynamic landscape of the pharmaceutical industry, CSPC Innovation Pharmaceutical Co Ltd stands as a beacon of innovation and ambition. Evolving from its roots in traditional pharmaceutical practices, the company has carved out a niche for itself by embracing cutting-edge research and development methodologies. At the core of their operations is an unwavering commitment to creating novel drugs that target complex medical challenges. This commitment is propelled by their significant investment in state-of-the-art R&D facilities and collaborations with leading academic institutions and biotech firms. By fostering a rich pipeline of new drugs, CSPC Innovation strives to maintain its competitive edge in a rapidly changing market, driven by both pressing healthcare needs and technological advancements. The company leverages its robust distribution network to bring these innovations to market, drawing upon a diverse portfolio that includes drugs for therapeutic areas such as oncology, cardiovascular health, and metabolic disorders. Revenue generation, therefore, hinges largely on the successful commercialization of these pharmaceutical products, through both direct sales and strategic partnerships. Additionally, CSPC Innovation engages in manufacturing and selling Active Pharmaceutical Ingredients (APIs), further diversifying its income streams. By balancing risk and opportunity, the company not only aims to meet the immediate health demands of its consumer base but also positions itself to capture long-term growth within the global healthcare sector, ensuring a steady influx of revenue and sustainability for future endeavors.

Intrinsic Value
17.74 CNY
Overvaluation 58%
Intrinsic Value
Price
C
Back to Top